Generation Financial Statements From 2010 to 2026

GBIO Stock

USD 5.62 0.02 0.35%

Generation Bio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Generation Bio's valuation are provided below:

Gross Profit

-32.4 M

Market Capitalization

37.9 M

Enterprise Value Revenue

5.103

Revenue

15.3 M

Earnings Share

(9.37)

We have found one hundred twenty available fundamental trends for Generation Bio, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to confirm Generation Bio's regular fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 17th of January 2026, Market Cap is likely to drop to about 77.2 M. In addition to that, Enterprise Value is likely to drop to about 96 M

Generation Bio Total Revenue

24.02 Million

Check Generation Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Generation Bio's main balance sheet or income statement drivers, such as Net Interest Income of 12.9 M, Interest Income of 6.5 M or Depreciation And Amortization of 4 M, as well as many indicators such as Price To Sales Ratio of 3.88, Dividend Yield of 0.0 or PTB Ratio of 0.77. Generation financial statements analysis is a perfect complement when working with Generation Bio Valuation or Volatility modules.

Build AI portfolio with Generation Stock

Check out the analysis of Generation Bio Correlation against competitors.

Generation Bio Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

295.2 M

265.9 M

182.8 M

Slightly volatile

Other Current Liabilities

11.5 M

11.6 M

7.9 M

Slightly volatile

Total Current Liabilities

22 M

40.3 M

15 M

Slightly volatile

Other Liabilities

12.4 M

17.2 M

8.6 M

Slightly volatile

Property Plant And Equipment Net

55.6 M

40.9 M

28.6 M

Slightly volatile

Current Deferred Revenue

6.9 M

12.2 M

4.1 M

Slightly volatile

Accounts Payable

1.2 M

1.3 M

1.6 M

Pretty Stable

Cash

109.4 M

87.7 M

56 M

Slightly volatile

Non Current Assets Total

60.4 M

44 M

31.8 M

Slightly volatile

Non Currrent Assets Other

3.2 M

3.1 M

2.6 M

Slightly volatile

Other Assets

4.7 M

9 M

4 M

Slightly volatile

Cash And Short Term Investments

228.8 M

213 M

146.9 M

Slightly volatile

Net Receivables

1.4 M

1.8 M

1.3 M

Pretty Stable

Common Stock Total Equity

4.2 K

6.9 K

2.9 K

Slightly volatile

Common Stock Shares Outstanding

7.3 M

7.7 M

11.1 M

Slightly volatile

Liabilities And Stockholders Equity

295.2 M

265.9 M

182.8 M

Slightly volatile

Non Current Liabilities Total

103.3 M

126.4 M

108 M

Pretty Stable

Capital Surpluse

878.3 M

836.4 M

300.2 M

Slightly volatile

Other Current Assets

4.2 M

7 M

2.6 M

Slightly volatile

Total Liabilities

125.3 M

166.7 M

123 M

Very volatile

Property Plant And Equipment Gross

42.8 M

67.3 M

24.6 M

Slightly volatile

Total Current Assets

234.9 M

221.8 M

151 M

Slightly volatile

Capital Stock

5.2 K

8.1 K

3.2 K

Slightly volatile

Net Working Capital

212.9 M

181.5 M

136 M

Slightly volatile

Common Stock

5.2 K

8.1 K

3.2 K

Slightly volatile

Property Plant Equipment

21.6 M

25.5 M

13.3 M

Slightly volatile

Inventory

4.6 M

4.4 M

1.7 M

Slightly volatile

Deferred Long Term Liabilities

362.4 K

499.1 K

225.3 K

Slightly volatile

Short Term Debt

15.7 M

15 M

4.6 M

Slightly volatile

Short and Long Term Debt Total

97.3 M

107.6 M

85.2 M

Slightly volatile

Non Current Liabilities Other

178.4 K

200.7 K

219.1 K

Slightly volatile

Generation Bio Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Interest Income

6.5 M

12.3 M

4.1 M

Slightly volatile

Depreciation And Amortization

4 M

5.7 M

2.2 M

Slightly volatile

Selling General Administrative

33.1 M

43.4 M

21.2 M

Slightly volatile

Other Operating Expenses

117.5 M

186.6 M

79.4 M

Slightly volatile

Research Development

74.4 M

70.5 M

49.6 M

Slightly volatile

Total Operating Expenses

117.5 M

186.6 M

79.4 M

Slightly volatile

Reconciled Depreciation

4 M

5.7 M

2.2 M

Slightly volatile

Cost Of Revenue

4.6 M

5.7 M

3.1 M

Slightly volatile

Selling And Marketing Expenses

18.6 M

21 M

22.9 M

Slightly volatile

Generation Bio Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Stock Based Compensation

15.3 M

16.8 M

9.3 M

Slightly volatile

Begin Period Cash Flow

101 M

83.1 M

52 M

Slightly volatile

Depreciation

4 M

5.7 M

2.2 M

Slightly volatile

Capital Expenditures

2.1 M

2.2 M

4.8 M

Pretty Stable

Total Cash From Financing Activities

213.8 K

225 K

87.6 M

Slightly volatile

End Period Cash Flow

112.2 M

90.2 M

58.4 M

Slightly volatile

Change To Netincome

36.6 M

34.8 M

12.8 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

3.88

4.08

7.2 K

Slightly volatile

Days Sales Outstanding

31.25

32.9

7 K

Slightly volatile

Stock Based Compensation To Revenue

0.8

0.84

52.6464

Slightly volatile

Capex To Depreciation

0.53

0.56

5.6881

Slightly volatile

EV To Sales

4.83

5.08

7.1 K

Slightly volatile

Payables Turnover

12.15

11.57

5.663

Slightly volatile

Sales General And Administrative To Revenue

2.07

2.18

138

Slightly volatile

Research And Ddevelopement To Revenue

3.37

3.54

13.6461

Slightly volatile

Capex To Revenue

0.13

0.14

44.8179

Slightly volatile

Cash Per Share

50.45

31.97

41.6213

Pretty Stable

Days Payables Outstanding

31.02

32.66

271

Slightly volatile

Income Quality

0.77

0.6726

0.7498

Slightly volatile

Current Ratio

6.01

6.33

11.2521

Pretty Stable

Receivables Turnover

12.06

11.48

2.5687

Slightly volatile

Debt To Equity

1.03

0.98

0.3769

Slightly volatile

Capex Per Share

0.39

0.41

1.4727

Slightly volatile

Revenue Per Share

2.82

2.69

0.7787

Slightly volatile

Interest Debt Per Share

9.38

12.64

4.8728

Slightly volatile

Debt To Assets

0.21

0.36

0.2051

Slightly volatile

Operating Cycle

31.25

32.9

7 K

Slightly volatile

Days Of Payables Outstanding

31.02

32.66

271

Slightly volatile

Ebt Per Ebit

1.06

0.9247

0.9732

Slightly volatile

Total Debt To Capitalization

0.25

0.47

0.2286

Slightly volatile

Debt Equity Ratio

1.03

0.98

0.3769

Slightly volatile

Quick Ratio

6.01

6.33

11.2521

Pretty Stable

Net Income Per E B T

0.78

0.89

0.9664

Slightly volatile

Cash Ratio

1.86

1.96

2.9267

Slightly volatile

Days Of Sales Outstanding

31.25

32.9

7 K

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

1.25

1.18

1.1347

Pretty Stable

Fixed Asset Turnover

0.53

0.5

0.1159

Slightly volatile

Debt Ratio

0.21

0.36

0.2051

Slightly volatile

Price Sales Ratio

3.88

4.08

7.2 K

Slightly volatile

Asset Turnover

0.0813

0.0774

0.0193

Slightly volatile

Generation Bio Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

77.2 M

81.2 M

414.5 M

Slightly volatile

Enterprise Value

96 M

101.1 M

409 M

Slightly volatile

Generation Fundamental Market Drivers

	Forward Price Earnings	7.874
	Cash And Short Term Investments	185.2 M

Generation Upcoming Events

	22nd of February 2024 Upcoming Quarterly Report	View
	8th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	22nd of February 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Generation Bio Financial Statements

Generation Bio investors utilize fundamental indicators, such as revenue or net income, to predict how Generation Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	12.2 M	6.9 M
Total Revenue	22.9 M	24 M
Cost Of Revenue	5.7 M	4.6 M
Stock Based Compensation To Revenue	0.84	0.80
Sales General And Administrative To Revenue	2.18	2.07
Research And Ddevelopement To Revenue	3.54	3.37
Capex To Revenue	0.14	0.13
Revenue Per Share	2.69	2.82
Ebit Per Revenue	(6.44)	(6.76)

Pair Trading with Generation Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Generation Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Generation Bio will appreciate offsetting losses from the drop in the long position's value.

Moving against Generation Stock

0.66	CSCO	Cisco Systems Sell-off Trend	Pair Corr
0.62	IBM	International Business	Pair Corr
0.61	AMGN	Amgen Inc	Pair Corr
0.56	BOF	BranchOut Food Common	Pair Corr
0.55	F	Ford Motor	Pair Corr

The ability to find closely correlated positions to Generation Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Generation Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Generation Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Generation Bio Co to buy it.

The correlation of Generation Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Generation Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Generation Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Generation Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Generation Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Generation Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Generation Bio Co Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Generation Bio Co Stock:

How To Invest In Generation

Details

Is Generation Stock a good investment?

Details

What is Generation Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Generation Bio Correlation against competitors.

You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Generation Bio. If investors know Generation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Generation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(9.37)

Revenue Per Share

2.277

Quarterly Revenue Growth

(0.79)

Return On Assets

(0.27)

Return On Equity

(0.81)

The market value of Generation Bio is measured differently than its book value, which is the value of Generation that is recorded on the company's balance sheet. Investors also form their own opinion of Generation Bio's value that differs from its market value or its book value, called intrinsic value, which is Generation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Generation Bio's market value can be influenced by many factors that don't directly affect Generation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Generation Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Generation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Generation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Generation Financial Statements From 2010 to 2026

Generation Bio Total Revenue

24.02 Million

Generation Bio Balance Sheet

Generation Bio Income Statement

Generation Bio Cash Flow Statement

Financial Ratios

Generation Bio Valuation Data

Generation Fundamental Market Drivers

Generation Upcoming Events

About Generation Bio Financial Statements

Pair Trading with Generation Bio

Moving against Generation Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY